赛和美康（北京）科技股份有限公司 募集资金年度存放与实际使用情况 的基证报告 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址:北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编: 100073 电话:(010) 51423818 传真: (010) 51423816 目 录 一、鉴证报告 二、关于募集资金年度存放与实际使用情况的专项报告 一兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址(location):北京市丰台区丽泽路20号丽泽 S0H0 B座20层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电话(tel):010-51423818 传真(fax):010-51423816 关于嘉和美康(北京)科技股份有限公司 募集资金年度存放与实际使用情况的鉴证报告 中兴华核字(2025)第 011594 号 嘉和美康(北京)科技股份有限公 ...

嘉和美康（北京）科技股份有限公司 章 程 2025 年 4 月 | 第一章 | 总则 1 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 股份 2 | | 第一节 | 股份发行 2 | | 第二节 | 股份增减和回购 4 | | 第三节 | 股份转让 5 | | 第四章 | 股东和股东会 6 | | 第一节 | 股东 6 | | 第二节 | 控股股东和实际控制人 8 | | 第三节 | 股东会的一般规定 9 | | 第四节 | 股东会的召集 12 | | 第五节 | 股东会的提案与通知 14 | | 第六节 | 股东会的召开 15 | | 第七节 | 股东会的表决和决议 18 | | 第五章 | 董事和董事会 22 | | 第一节 | 董事的一般规定 22 | | 第二节 | 董事会 25 | | 第三节 | 独立董事 29 | | 第四节 | 董事会专门委员会 32 | | 第六章 | 高级管理人员 33 | | 第七章 | 财务会计制度、利润分配和审计 35 | | 第一节 | 财务会计制度 35 | | 第二节 | 内部审计 39 | | 第三节 | 会计师事务所 ...

嘉和美康（北京）科技股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范公司行为，保证股东依法行使职权，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司治理 准则》和《上市公司股东会规则》以及其他法律、行政法规和公司章程的规定， 制定本规则。 第二条 公司应当严格按照法律、行政法规、公司章程的规定召开股东会， 保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和公司章程规定的范围内行使职权。 第二章 股东会的一般规定 第四条 股东会是公司的最高权力机构，依法行使下列职权： 1 （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； （七）修改公司章程； （八）对公司聘用、解聘承办公司审计业务的会计师事务所作出决议； （九）审议批准 ...

嘉和美康（北京）科技股份有限公司 董事会议事规则 第一章 总则 第一条 为明确公司董事会的职责权限，规范公司董事会的议事方式和决策 程序，促使公司董事和董事会有效地履行职责，提高公司董事会规范运作和科学 决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》、《上市公司治理准则》和证券交易所股票上市规则及公司章程 等有关规定，制定本规则。 第二章 董事会的组成和职权 第二条 公司依法设立董事会，董事会对股东会负责。 第三条 公司董事会由 7 名董事组成，其中独立董事 3 名。 第四条 董事会行使下列职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （九）聘任或者解聘公司总经理、董事会秘书及其他高级管理人员，并决定 1 其报酬事项和奖惩事项；根据总经理的提名，决定聘任或者解聘公司副总经理、 财务负责人等高级管理人员，并决定其报酬事项和奖惩事项； （十）制定公司的基本管理制度； （十一）制订公司章程的修改方案； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或其他证券及上 ...

2024 年度独立董事述职报告 作为嘉和美康（北京）科技股份有限公司（以下简称"公司"或"嘉和美康"） 的独立董事，2024年我严格按照《公司法》《证券法》《上市公司治理准则》、 《上市公司独立董事管理办法》以及《公司章程》、公司《独立董事工作制度》 的相关要求，在履职过程中做到勤勉尽责，积极参加股东大会、董事会和各专业 委员会会议，就有关事项发表同意的意见，充分发挥独立董事的作用，切实维护 全体股东尤其是中小股东的合法权益。现将2024年度履职情况报告如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 石向欣先生，1956年8月出生，中国国籍，无境外永久居留权，北京工业大 学学士，北京大学硕士。1972年5月至1976年12月任北京平谷插队民办教师；1976 年1月至1981年8月任北京汽车塑料件厂电工及助理；1985年9月至1987年11月任 中国人民大学教师；1987年12月至1995年5月任国家轻工业部秘书；1995年5月至 2005年12月任北京华讯集团副总裁；2005年7月至今任北京大洋信通科技有限公 司执行董事、总经理；2003年11月至今任北京红金石科技有限公司总经理；201 ...

王韵先生，1976年11月出生，中国国籍，无境外永久居留权，中国人民大学 法律硕士学位。1999年9月至2011年6月任北京市乾坤律师事务所专职律师；2011 年6月至2016年6月任北京市大器律师事务所合伙人；2016年6月至今任北京市中 永律师事务所高级合伙人；2022年5月至今担任嘉和美康独立董事。 嘉和美康（北京）科技股份有限公司 2024 年度独立董事述职报告 作为嘉和美康（北京）科技股份有限公司（以下简称"公司"或"嘉和美康"） 的独立董事，2024年我严格按照《公司法》、《证券法》、《上市公司治理准则》、 《上市公司独立董事管理办法》以及《公司章程》、公司《独立董事工作制度》 的相关要求，在专业委员会、董事会、股东大会日常工作及重要决策中尽职尽责， 并对董事会的相关事项发表了意见，从公司整体利益出发，发挥了独立董事的应 有作用，维护了公司和全体股东特别是中小股东的合法权益。现将2024年度履行 独立董事职责工作情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 （二）独立性情况 作为公司的独立董事，我本人及直系亲属均不在公司或其附属企业担任除独 立董事之外的其他职务；没 ...

（一）工作履历、专业背景以及兼职情况 任宏女士，1974年9月出生，中国国籍，无境外永久居留权，1995年于上海 师范大学财务会计专业毕业，2003年于首都经贸大学会计学本科毕业，2010年于 中国矿业大学（北京）会计学研究生毕业，获得管理学硕士学位。2003年6月至 2011年6月任北京惠通陆华汽车销售服务有限公司财务总监岗位；2011年7月至今 任北京中珩迦汽车（集团）有限公司副总经理岗位；2022年5月至今担任嘉和美 康独立董事。 （二）独立性情况 嘉和美康（北京）科技股份有限公司 2024 年度独立董事述职报告 作为嘉和美康（北京）科技股份有限公司（以下简称"公司"或"嘉和美康"） 的独立董事，2024年我严格按照《公司法》《证券法》《上市公司治理准则》《上 市公司独立董事管理办法》以及《公司章程》、公司《独立董事工作制度》的相 关要求，在专门委员会、董事会、股东大会日常工作及重要决策中尽职尽责，并 对董事会的相关事项发表了意见，从公司整体利益出发，发挥了独立董事的应有 作用，维护了公司和全体股东特别是中小股东的合法权益。现将2024年度履行独 立董事职责工作情况汇报如下： 一、独立董事的基本情况 作 ...

Financial Performance - The consolidated net profit attributable to the parent company for the year ended December 31, 2024, was -256,117,402.41 RMB, indicating a loss[5]. - The undistributed profits on a consolidated basis amounted to -354,193,915.51 RMB, while the parent company's undistributed profits were 15,702,223.45 RMB[5]. - Due to the negative net profit, the company will not distribute profits for the year 2024, pending approval from the shareholders' meeting[5]. - The company's operating revenue for 2024 was approximately ¥591.94 million, a decrease of 14.85% compared to ¥695.18 million in 2023[21]. - The net profit attributable to shareholders for 2024 was a loss of approximately ¥256.12 million, a significant decline from a profit of ¥32.28 million in 2023, representing a decrease of 893.31%[21]. - The basic earnings per share for 2024 was -¥1.86, down 908.70% from ¥0.23 in 2023[23]. - The net cash flow from operating activities improved by ¥75.47 million compared to the previous year, reaching -¥67.63 million in 2024[26]. - The company's total assets at the end of 2024 were approximately ¥2.49 billion, a decrease of 5.98% from ¥2.65 billion at the end of 2023[22]. - The company reported a significant increase in asset impairment provisions due to cautious management practices, impacting profit metrics[24]. - The company reported a net loss attributable to shareholders of 256.12 million yuan and a net loss of 261.38 million yuan after deducting non-recurring gains and losses, primarily due to deferred customer demand and increased R&D investments[109]. Research and Development - Research and development expenses accounted for 37.59% of operating revenue in 2024, an increase of 4.87 percentage points from 32.72% in 2023[23]. - The company invested heavily in R&D, focusing on medical AI technology and product iterations, which increased the technical content and market competitiveness of its products[35]. - The company applied for 53 new invention patents and obtained 13 invention patent authorizations during the reporting period, bringing the total number of authorized invention patents to 58[87]. - Total R&D investment amounted to ¥222,525,583.83, a decrease of 2.16% compared to the previous year, with R&D investment as a percentage of operating income increasing by 4.88 percentage points to 37.59%[88]. - The company has developed multiple specialized electronic medical record (EMR) products, including those for anesthesia, intensive care, and emergency medicine, enhancing its market position[100]. - The company has developed a cloud-native platform that enables automatic fault removal and reconstruction, showcasing strong self-healing capabilities and scalable deployment across multiple hospitals[86]. - The company is focusing on intelligent upgrades of electronic medical records, aiming for comprehensive leadership in depth, breadth, efficiency, and quality[155]. Market Position and Strategy - The company has maintained its leading position in the Chinese electronic medical record market for 10 consecutive years, ranking first in 2023[54]. - In the medical big data solutions market, the company has been in the top three for five consecutive years, further enhancing its market position and brand value[54]. - The company aims to drive high-quality hospital development through technology innovation and collaboration with major AI and computing power partners[53]. - The company is focused on developing advanced digital solutions to enhance patient care and streamline hospital management processes[92]. - The company is exploring mergers and acquisitions to strengthen its market position and diversify its product offerings[164]. - The company plans to enhance its market presence by enhancing product functionalities and user engagement through upgraded systems and new features[13]. - The company anticipates continued growth in the medical informationization sector driven by supportive government policies and a focus on clinical needs[146]. Risks and Compliance - The company has detailed potential risks in the report, which investors should consider[3]. - The company faces risks related to market competition, with a small market share in the overall medical informationization market, despite ranking first in the EMR segment and third in the medical big data solutions segment[112]. - The company has identified potential risks in customer expansion, project implementation without signed contracts, and seasonal fluctuations in performance due to project acceptance timing[114]. - The company has a risk of increased bad debt losses due to weak accounts receivable recovery capabilities from both medical institutions and third-party non-medical institutions[116]. - The company faces risks from changes in tax incentives, which could increase tax liabilities and adversely affect operating performance[118]. - The governance structure of the company is continuously being improved to ensure compliance with relevant laws and regulations[159]. Technological Innovations - The company is leveraging advanced AI capabilities to improve diagnostic accuracy and automate administrative processes, thereby reducing the burden on healthcare professionals[76]. - The company has developed a unified big data processing architecture that integrates various types of original data, facilitating efficient management and real-time analysis of massive datasets[17]. - The integration of new technologies such as AI, big data, and cloud computing is significantly improving the efficiency and effectiveness of medical information systems[79]. - The company is focusing on the integration of cloud computing, big data, artificial intelligence, and IoT to drive innovation in medical software systems[80]. - The company has developed innovative technologies, including a medical time-series data processing engine and a clinical event search engine, which have doubled the efficiency of disease-specific database construction[50]. Financial Management - The company has a total asset value of 2.49 billion yuan and a net asset value of 1.56 billion yuan as of the end of the reporting period[113]. - The company has accumulated undistributed losses of CNY 35.42 million at the consolidated level, which may affect future profit distribution[118]. - The company has a stock price decline risk with a provision for inventory impairment of CNY 58.57 million, primarily related to its medical information business[117]. - The company’s financing activities generated a net cash flow of CNY 95.04 million, an increase of 48.65% compared to CNY 63.93 million in the previous year[123]. - The company has a negative cash flow from investment activities of CNY 197.33 million, significantly higher than negative CNY 63.97 million in the previous year[123]. Employee Management - The company has a total of 1,865 employees, with 50 in the parent company and 1,815 in major subsidiaries[184]. - Among the employees, 1,539 are technical personnel, accounting for 82.4% of the total workforce[184]. - The company has established a salary management system to optimize its compensation structure and enhance employee motivation[186]. - The total remuneration for core technical personnel at the end of the reporting period was 3.9492 million RMB[173]. - The company has implemented a training program to enhance professional knowledge and skills among employees[187]. Future Outlook - Future guidance indicates a positive outlook, with expectations for continued growth in user data and market share[164]. - The company is investing 50 million in R&D for new technologies aimed at enhancing user experience[165]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online engagement by mid-2024[168]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 100 million allocated for potential deals[165].

Financial Performance - The total revenue for the reporting period was 600.72 million, a decrease of 14.85% compared to the previous year’s 695.18 million[2] - The net profit attributable to the parent company was revised to -256.12 million, a decrease of 70.77% from the previous estimate of -145.00 million[5] - The net profit attributable to the parent company after deducting non-recurring gains and losses was revised to -261.38 million, a decrease of 67.23% from the previous estimate of -156.00 million[5] - The basic earnings per share were reported at -1.09 yuan, a decrease of 908.70% compared to the previous year[2] - The weighted average return on net assets was -8.55%, a decrease of 16.94 percentage points from the previous year[2] Assets and Equity - Total assets at the end of the reporting period were 2,617.29 million, a decrease of 5.99% from the previous year’s 2,645.63 million[3] - The equity attributable to the parent company was 1,674.27 million, a decrease of 14.61% from the previous year’s 1,821.58 million[3] Accounting Issues - The company identified accounting errors in the financial statements for 2022 and 2023, leading to adjustments that reduced net profit and other financial metrics[6] - The company will enhance supervision and training on accounting standards to ensure the accuracy of future earnings forecasts[8] Investor Relations - The company expressed sincere apologies to investors for the impact of the earnings forecast and report corrections[8]

Financial Performance - The company's operating revenue for Q1 2025 was ¥101,199,221.48, representing a decrease of 17.43% compared to ¥122,559,648.25 in the same period last year[4] - The net profit attributable to shareholders was -¥17,433,344.55, worsening from -¥11,850,583.19 year-over-year[4] - The net cash flow from operating activities was -¥94,058,756.82, slightly improved from -¥96,963,002.49 in the previous year[4] - Total revenue for Q1 2025 was CNY 101,199,221.48, a decrease of 17.4% compared to CNY 122,559,648.25 in Q1 2024[18] - Net loss for Q1 2025 was CNY 25,433,828.07, compared to a net loss of CNY 16,002,665.06 in Q1 2024, representing an increase in loss of 58.9%[19] - The total comprehensive income for the first quarter of 2025 was -25,433,828.07 RMB, compared to -16,002,665.06 RMB in the first quarter of 2024, indicating a decline[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,417,566,990.38, down 2.80% from ¥2,487,288,265.92 at the end of the previous year[5] - The company's total assets decreased to CNY 2,417,566,990.38 from CNY 2,487,288,265.92, a decline of 2.8%[17] - Total liabilities decreased to CNY 922,834,172.17 from CNY 967,121,619.64, a reduction of 4.6%[16] - The company's total equity decreased to CNY 1,494,732,818.21 from CNY 1,520,166,646.28, a decline of 1.7%[17] Cash Flow - The cash flow from operating activities showed a significant decline, impacting liquidity and operational flexibility[19] - Cash inflow from operating activities totaled 121,181,325.80 RMB in Q1 2025, down from 130,917,730.32 RMB in Q1 2024[21] - The net cash flow from investing activities was -10,332,107.19 RMB in Q1 2025, an improvement from -55,200,335.12 RMB in Q1 2024[22] - Total cash outflow from operating activities was 215,240,082.62 RMB in Q1 2025, compared to 227,880,732.81 RMB in Q1 2024[22] - The company received 77,476,300.00 RMB from financing activities in Q1 2025, down from 106,381,513.11 RMB in Q1 2024[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,860[9] - The top shareholder, Xia Jun, holds 24,750,839 shares, representing 17.99% of total shares[10] - The second-largest shareholder, Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, holds 16,812,069 shares, accounting for 12.22%[10] - The company has a total of 9,861,786 shares held by Hongyun Jiukang Data Technology (Beijing) Co., Ltd., which is 7.17% of total shares[10] - The total number of shares held by the top 10 shareholders includes significant stakes from various investment funds, indicating strong institutional interest[11] Research and Development - Research and development expenses totaled ¥47,758,469.77, a decrease of 20.10% from ¥59,773,809.35, accounting for 47.19% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 34,429,266.72, up 7.3% from CNY 32,077,752.04 in Q1 2024[18] Management and Strategy - The company has committed to ensuring the accuracy and completeness of its financial information, with management taking legal responsibility for the report[2] - The company has not disclosed any significant new strategies or product developments during the earnings call[13] - The company plans to focus on enhancing data resources and technology development to drive future growth[18] - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its market position[19] Earnings Per Share - The diluted earnings per share for the period was -¥0.13, compared to -¥0.09 in the same period last year[5] - The company reported a basic and diluted earnings per share of -0.13 RMB for Q1 2025, compared to -0.09 RMB in Q1 2024[20] Other Information - The company reported non-recurring gains and losses totaling ¥526,350.33 for the period[7] - The company did not report any net profit from the merged entity prior to the merger, with previous net profit also reported as 0 RMB[20] - The company has not adopted new accounting standards or interpretations for the year 2025[23] - There are no other important reminders regarding the company's operational situation during the reporting period[13]